© 1997 American Heart Association, Inc.
Articles |
Interaction of Diet and Genes in Atherogenesis Report of an NHLBI Working Group
From the Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, New York (A.T., C.W.); the National Heart, Lung, and Blood Institute, National Institute of Health, Bethesda, Maryland (D.A.B., M.W.). The participants of the working group are: Alan Tall, MD (Chair), Department of Medicine, College of Physicians & Surgeons of Columbia University, New York, NY 10032; John M. Dietschy, MD, University of Texas Health Science Center, Southwestern Medical School, Dallas, TX 75235; Scott M. Grundy, MD, PhD, Center for Human Nutrition, University of Texas Health Center, Dallas, TX 75235; Aldons J. Lusis, PhD Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90024; P. Ruth McPherson, MD, PhD, University of Ottawa Heart Institute, Ottawa, Ontario, Canada K1Y 4E9; Timothy F. Osborne, PhD, Department of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA 92717; Lawrence L. Rudel, PhD Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27517; Ernst J. Schaefer, MD, Lipid Metabolism Laboratory, Tufts University, Boston, MA 02111; NHLBI Staff: Momtaz Wassef, PhD, Deborah Applebaum-Bowden, PhD, Atherosclerosis Research Group, Abby Ershow, Sc.D., Cardiovascular Homeostasis and Bionutrition Research Group, Division of Heart and Vascular Diseases, Rockledge II, MSC 7956, Bethesda, MD 20892.
 |
Abstract |
|---|
 Top Abstract IntroductionReferences |
|---|
Abstract Recent advances in genetics and information emerging from the Human Genome Project make it feasible to examine the importance of dietary-genetic interactions in the development of atherosclerosis. In the opinion of the Working Group, three approaches are necessary to examine this concern. The first approach utilizes animal models to map and identify candidate genes involved in dietary responsiveness and atherogenesis. The second approach involves the evaluation of these genes in specific physiological processes involved in dietary responsiveness and atherogenesis. Finally, the third approach is to extend the studies performed in animal models to human populations using linkage or association studies.
Key Words: atherogenesis • diet • genes
|
Introduction |
|---|
|
TopAbstractIntroductionReferences |
|---|
Atherosclerosis is a multifactorial disease in which complex interactions between environmental and genetic factors appear to play important roles in the pathogenesis. While certain dietary factors have been implicated in development of the disease, epidemiological and genetic studies indicate that there are wide differences in interindividual responses to such factors. Environmental variation and genetic heterogeneity have hampered human studies to identify possible genetic determinants of dietary responsiveness. The recent advancement of rat and mouse models as tools for genetic studies offers the potential for in-depth investigation of complex diet/gene interactions in the presence of one or more risk factors for atherosclerosis. In addition, progress in the Human Genome Project promises to facilitate the identification of mutant genes underlying complex quantitative responses to environmental stimuli. The identification of genes determining dietary responsiveness in rodents will likely lead to a greater understanding of responsiveness in humans.
The NHLBI recently held a Working Group meeting to examine dietary and genetic interactions affecting atherogenesis, and to determine areas in which further research is warranted. In this report, we provide a short overview of the field and discuss priority areas for future research as recommended by the Working Group.
|
|
TopAbstractIntroductionReferences |
|---|
Background
Epidemiological, clinical, and biochemical studies have shown that dietary saturated fat and cholesterol raise total plasma cholesterol and LDL-C levels and induce atherosclerosis, whereas dietary polyunsaturated fatty acids do the reverse. Nevertheless, there is considerable evidence in both humans and monkeys that some individuals are more sensitive to a high fat, high cholesterol diet than others.1–8 This variability in plasma lipid response to diet has profound implications for an individual's susceptibility to atherosclerosis and its complications, and for predicting whether an individual will respond favorably to dietary treatment of hyperlipidemia. While it is highly likely that there is a major genetic component of dietary responsiveness, the genes involved and their common variants are largely unknown.
Human studies of dietary responsiveness of plasma lipoproteins have focused mainly on a few candidate genes. The best studied of these is apo E. Substantial population data demonstrate that heterozygosity or homozygosity for the E4 allele is associated with higher mean plasma cholesterol levels and more CHD, whereas heterozygosity for the E2 allele results in lower mean plasma cholesterol levels and apparently delayed CHD.9–11 The relationship of apo E isoforms to cholesterol levels is much more evident in populations consuming high fat, high cholesterol diets. Accordingly, a number of human clinical and population studies have determined the effect of apo E genotype on sensitivity to dietary cholesterol and fat. The results of these studies indicate that the E4 allele is associated with increased levels of LDL-C in response to dietary cholesterol relative to other apo E alleles12–14; one study suggested that the hyperresponsiveness was due to increased cholesterol absorption.15 However, inconsistent results have been reported from a number of other studies,16–19 suggesting that the apo E isoform is a minor determinant of dietary sensitivity in some populations.
Evidence for the involvement of two other candidate genes, the apo A-IV and apo B genes, in the genetic variability of dietary responsiveness has also been reported. Carriers of the apo A-IV-2 allele exhibited impaired cholesterol lowering in response to a low fat, low cholesterol diet20 and attenuated hypercholesterolemia in response to a high cholesterol diet relative to carriers of the apo A-IV-1 allele.21 Apo B polymorphisms were observed to affect plasma lipoprotein responses to low saturated fat feeding in males. Thus, homozygous male carriers of the apo B signal peptide 27 allele exhibited greater responses than homozygous carriers of the apo B signal peptide 24 allele or heterozygotes.22 Further studies of these genetic variants will be necessary to elucidate the mechanisms through which the genes regulate responsiveness to diet.
Additional studies have focused on interindividual differences in metabolic responses to dietary saturated fat and cholesterol. The role of cholesterol absorption efficiency in determining diet-induced plasma lipoprotein levels remains unclear; in one study, hyperresponders exhibited increased efficiency while in another study they did not.23,24 Impaired regulation of cholesterol biosynthesis1,3,25 and increased production of apo B26 were also observed in populations of hyperresponders relative to hyporesponders. Finally, direct effects of dietary saturated fatty acids on LDL receptor activity and dietary cholesterol on LDL receptor mRNA levels were reported in animal models.27–29 Consistent with these reports, a recent human study found that subjects most sensitive to the hypercholesterolemic effects of dietary saturated fat exhibited low LDL apo B fractional catabolic rates, suggestive of marked down regulation of hepatic LDL receptors.5 The wide range of metabolic responses to dietary fat and cholesterol documented by these studies is likely due to differences in diet/dietary regimen as well as genetic heterogeneity between populations (or animal models) studied. Clearly, metabolic responses to dietary fat and cholesterol are complex; further elucidation of the differences between hyperresponders and hyporesponders may be facilitated by preliminary studies in animal models.
Another important area in the study of the interaction of genes and nutrition in atherogenesis is individual susceptibility to weight gain in response to overfeeding. Both obesity and diabetes are significant risk factors for atherosclerosis. Recent studies in animal models indicate that diet may influence the expression of a number of genes involved in the expression of these traits, but the genes involved have yet to be identified.30,31 In humans, concordance of weight gain in response to overfeeding was observed among identical twins but not among unrelated volunteers, suggesting a genetic contribution to the population variance in diet-induced weight gain.32 Advances in animal models may shed light on the genetic determinants of human weight gain and the relationship between obesity, diabetes, and atherosclerosis.
New Opportunities for Understanding Gene-Diet Interactions
Recent advances in genetics make it feasible to map and identify
genes regulating complex traits such as dietary responsiveness of
plasma lipoproteins. Firstly, the development of highly
polymorphic, easy to type, microsatellite markers distributed
throughout the genome of humans,33
mice,34 and rats35,36 has
vastly altered the way in which genetic studies are
approached.37,38 In particular, genome wide
searches using animal models reduces the environmental and genetic
complexity of a trait, increasing the probability of success in gene
mapping. Secondly, increasingly dense expression maps facilitate
candidate gene identification,39,40 and the
ability to perform targeted mutagenesis of these genes allows direct
testing in animal models.41,42 Thirdly, extended
knowledge of homology relationships between human and other genomes
(especially mouse)43 allows the testing of human
homologs of candidate genes identified in animal models to determine
the relevance of these genes in human physiology and disease. For
example, genetic markers can be identified in homologous regions of the
human genome and tested for linkage in family studies or sib-pair
analyses. Finally, targeted mutagenesis can also be used to
create new animal models based on mutations identified in human
studies. The ability to induce specific mutations provides novel
opportunities for examining the effect of a mutation in different
defined genetic backgrounds and exploring the
physiological consequences of different
combinations of mutant genes.
What is the significance of understanding genetic-dietary interactions at the molecular level? There are at least three important points. The first is that knowledge of genetic factors will help pinpoint important processes and pathways involved in atherosclerosis. Knowledge of such pathways is likely to contribute to better management of plasma lipoprotein levels and the development of new therapies. The second is that such studies promise to provide new, more specific diagnostic tests for identification of individuals at risk for the disease. Thirdly, studies of genetic-dietary interactions may reveal new information about basic homeostatic mechanisms in mammals.
Recommended Priority Areas for Future Research
1. Use of Animal Models to Identify Genes Determining Dietary
Responsiveness
As mentioned above, an increasingly important approach to the study of complex traits such as dietary responsiveness of plasma lipoprotein levels is to utilize animal models to map and identify important genes and then to test the homologous genes in human populations. Critical to the success of dietary studies, the use of animal models allows for strict dietary control. Semi-purified diets can be used and food intake monitored for comparison across studies. Another important point is that the use of animal models allows for selective breeding, decreasing the genetic complexity of a trait.
Mouse and rat models have been specifically developed for genetic studies (in contrast to nonhuman primates, hamsters, and rabbits).44–46 Both species are easy to breed and relatively inexpensive to maintain. Hundreds of different inbred strains have been produced and maintained over the years, and many of these strains exhibit variations in relevant traits including plasma lipoprotein levels, dietary responsiveness, obesity, and atherosclerosis.46–50 The mouse genetic and physical maps have been developed to a similar state as those of human: more than 15,000 genes and genetic markers have been mapped34,40 and yeast artificial chromosome clones are available covering most parts of the genome.51 While the rat has long been the model of choice for physiological and nutritional studies (because its larger size facilitated experimental intervention), the organism has lagged far behind the mouse as a genetic tool. However, the recent convergence of molecular genetics and other fields of biomedical research have increased efforts to develop the rat for genetic studies. Microsatellite markers are being developed rapidly; the current genetic map contains more than 1000 genes and markers covering most of the genome.35,36 Finally, well-established technology for gene manipulation makes these rodent models valuable genetic tools.
Rat and mouse models have been employed recently in genetic searches for susceptibility genes for atherosclerosis-related traits. Genetic crosses between strains differing in blood pressure, plasma lipoprotein profiles, obesity and gallstone formation have led to the identification of chromosomal regions likely to contain QTLs.30,31,52–60 In contrast to studies in humans, fine structure mapping and positional cloning of the genes underlying the QTLs are feasible because individual loci can be isolated on common genetic backgrounds as "congenic strains".58,61,62 Various dietary hyperresponsive and hyporesponsive strains have been identified in feeding studies.47,48,50 These strains can now be used as progenitors of genetic crosses to identify genes contributing to variations in dietary responsiveness using a whole genome approach.
Targeted mutagenesis in rodent models allows for the direct testing of candidate genes and isolated functional studies. Transgenic and knock-out mouse models of atherosclerosis have provided supportive evidence for early hypotheses about the roles of lipoproteins in the development of the disease. For example, targeted mutations of the apo E and LDL receptor genes, and overexpression of apo B resulted in mice with hypercholesterolemia and increased susceptibility to atherosclerotic lesion development (reviewed in45). In addition, mice with high HDL cholesterol levels due to overexpression of apo AI in both wild type and apo E deficient backgrounds were resistant to lesion formation relative to control strains. Importantly, studies of genetically engineered mouse models have suggested that qualitative differences in lipoprotein particles might be important in determining the relative atherogenicity of particles45 and have led to the identification of genes, which may be important in lipoprotein remodeling.63–66 Similarly, individual genetic components of dietary responsiveness can be studied using planned genetic modifications in rodents. The influence of these genes on physiological processes such as cholesterol absorption and biosynthesis, bile acid synthesis, and body energy metabolism can be directly assessed.
The utility of mouse models for studying the relationship between dietary responsiveness and atherogenesis is limited by the relative resistance of naturally occurring strains to lesion development. Naturally occurring "susceptible" strains develop lesions only after feeding a diet high in cholesterol and containing cholic acid.49 Studies of dietary responsiveness and atherosclerosis could be carried out using more moderate diets in genetically-modified, atherosclerosis-susceptible strains (such as apo E or LDL receptor knock-out mutants). Alternatively, functional studies could be carried out using other animal models. There is strong evidence in nonhuman primates for a genetic component of dietary responsiveness of plasma lipoprotein levels and atherogenesis.6–8 Relevant physiological processes could be examined in detail in nonhuman primate models where invasive studies to isolate individual components of the metabolic response under strict dietary control can be accomplished.
2. Evaluation of Specific Molecular Processes Underlying Dietary Responsiveness
A number of different physiological processes are likely to be responsible for dietary responsiveness. These include, but are not limited to, cholesterol absorption and biosynthesis, bile acid synthesis, sterol-mediated regulation of gene expression, and the control of body energy metabolism. Although progress has been made, an overall understanding of each of these physiological processes is greatly lacking. For instance, evidence from patients with the genetic disorder phytosterolemia, in which there is abnormal absorption of dietary plant sterols, and studies with highly potent drugs inhibiting cholesterol absorption, clearly indicate that there are specific molecules mediating intestinal cholesterol absorption67–69; however, the nature of these molecules is unknown.
Recently, novel candidate genes for the regulation of some of these processes have been identified and evaluated in rodent and yeast model systems. Normal cholesterol absorption and esterification in ACAT knock-out mice suggested the existence of additional ACAT-related genes.70 Consistent with this hypothesis, novel ACAT homologous sequences have been identified;71 the role of these genes in cholesterol absorption and dietary responsiveness is under investigation. Novel transcription factors, such as the sterol regulatory element binding proteins, have been postulated to mediate responses to high or low cholesterol diets and control fatty acid and energy metabolism.72–74 The LXR75 and uncoupling protein-276 genes are two additional examples of recently identified candidate genes for dietary responsiveness. Further studies of these genes and the identification of new genes will provide insight to the genetic components and physiological pathways determining inter-individual responsiveness to dietary changes.
3. Genetic Basis of Dietary Hyperresponsiveness and Hyporesponsiveness in Humans.
The most common form of hyperlipidemia present in patients with CHD is FCHL. This disorder appears to have a strong familial component that is elicited by nutritional factors such as excess total calories (leading to obesity), saturated fatty acids, and cholesterol. Although these eliciting factors are present in the general population, FCHL develops in only a subgroup of the population. To date, a single genetic defect has not been discovered to account for the high frequency of FCHL in the population. However, the genetic contribution is so strong that the condition appears to be monogenic in family studies. One explanation for this observation could be genetic heterogeneity (different major genes affecting VLDL-C and LDL-C metabolism in different families). Early investigations suggested that FCHL is the result of overproduction of apo B-containing lipoproteins in the liver. More recent studies in transgenic animals point to a catabolic defect of triglyceride-rich lipoproteins as the site of one likely genetic abnormality.77 For example, the heterozygous form of lipoprotein lipase deficiency has been reported to be accompanied by the FCHL phenotype in some individuals. This phenotype has also been noted in transgenic mice overexpressing apo CIII (an inhibitor of lipoprotein lipase) in a setting of reduced LDL receptor activity. FCHL exemplifies the need to identify new candidate genes and specific pathways involved in dietary responsiveness.
Candidate genes identified in animal studies can be tested in humans, under carefully controlled dietary conditions. Relatively little information is available regarding the heritability of dietary responsiveness in humans. Estimates of the number or nature of genes involved could be obtained from genome scans using animal models. Then, pilot studies can be designed using small numbers of twins or nuclear families to test hypotheses and experimental conditions (including composition and duration of diet). The use of diets having markedly different nutritional compositions in crossover study designs will facilitate the detection of differences between study groups. Experience indicates that, in addition to careful monitoring of diet, it will be important to perform repeated measurements of responses. Dietary studies using obese and diabetic (Type II diabetes) populations would be of considerable interest since these conditions are likely to be important factors modifying dietary responsiveness. These pilot studies will likely provide important information necessary for carrying out larger sib-pair linkage analyses or association studies to test candidate genes or map new genes underlying dietary responsiveness. The long-term goals of these studies would be to determine the dietary-genetic interactions affecting atherosclerosis.
|
Selected Abbreviations and Acronyms |
|---|
|
Received February 11, 1997; accepted May 21, 1997.
|
References |
|---|
|
TopAbstractIntroductionReferences |
|---|
1. Mistry P, Miller N, Laker M, Hazzard W, Lewis B. Individual variation in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. J Clin Invest. 1981;67:493–502.
2. Beynen AC, Katan MB, Van Zutphen LFM. Hypo- and hyperresponders: individual differences in the response of serum cholesterol concentration to changes in diet. Adv Lipid Res. 1987;22:115–171.[Medline] [Order article via Infotrieve]
3. McNamara DJ, Kolb R, Parker TS, Batwin H, Samuel P, Brown CD, Ahrens EH. Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. J Clin Invest. 1987;79:1729–1739.
4. Katan MB, Berns MAM, Glatz JFC, Knuiman JT, Nobels A, deVries JHM. Congruence of individual responsiveness to dietary cholesterol and to saturated fat in humans. J Lipid Res. 1988;29:883–892.[Abstract]
5.
Denke MA, Grundy SM. Individual responses to a
cholesterol-lowering diet in 50 men with moderate
hypercholesterolemia. Arch Int Med. 1994;154:317–325.
6. Colvin PL Jr, Spray BJ, Miller NE. Plasma low density lipoprotein cholesterol concentration in cynomolgus monkeys; differing effects of age and body weight in animals consuming low and high cholesterol diets. Atheroscler. 1994;111:191–197.
7. Spray BJ, Morgan TM, Clarkson TB. Genetic estimates for plasma lipids and lipoproteins in cyanomolgus monkeys under assertative mating. J Med Primatol. 1994;23:450–457.[Medline] [Order article via Infotrieve]
8.
Rudel LL, Johnson FL, Sawyer JK, Wilson MS, Parks JS.
Dietary polyunsaturated fat modifies low density lipoproteins and
reduces atherosclerosis of nonhuman primates with high
and low diet responsiveness. Am J Clin Nutr. 1995;62:463S–470S.
9. Uttermann G, Pruin N, Steinmetz A. Polymorphism of apoprotein E III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin Genet. 1979;15:63–72.[Medline] [Order article via Infotrieve]
10.
Robertson FW, Cumming AM. Effects of apoprotein E
polymorphism on serum lipoprotein concentration.
Arteriosclerosis. 1985;5:283–292.
11. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring Study. JAMA. 1994;272:1666–1671.
12. Lopez-Miranda J, Ordovas JM, Marta P, Lichtenstein AH, Clevidence B, Judd JT, Schaefer EJ. Effects of apolipoprotein E phenotype on diet-induced lowering of plasma low-density lipoprotein cholesterol. J Lipid Res. 1994;35:1965–1975.[Abstract]
13. Gylling H, Miettinen TA. Cholesterol absorption and synthesis related to low density lipoprotein metabolism during varying cholesterol intake in man with different apoE phenotype. J Lipid Res. 1992;33:1361–1371.[Abstract]
14. Manttari M, Koskinen P, Ehnholm C, Huttunen JK, Manninem V. Apolipoprotein E polymorphism influences the serum cholesterol response to dietary intervention. Metabolism. 1991;40:217–221.[Medline] [Order article via Infotrieve]
15. Kesaniemi YA, Enholm C, Miettinen TA. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest. 1987;80:578–581.
16. Martin L, Connelly PW, Nancoo N, Zhang ZJ, Maguire G, Quinet E, Tall A, Marcel YL, McPherson R. Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apolipoprotein E genotype. J Lipid Research. 1993;34:437–446.[Abstract]
17. Friedlander Y, Berry EM, Eisenbert S, Stein Y, Leitersdorf E. Plasma lipids and lipoproteins response to a dietary challenge; analysis of four candidate genes. Clin Genet. 1995;47:1–12.[Medline] [Order article via Infotrieve]
18.
Zambon D, Ros E, Casals E, Sanllehy C, Bertomeu A,
Campero I. Effect of apolipoprotein E polymorphism on the serum
lipid response to a hypolipidemic diet rich in
monounsaturated fatty acids in patients with
hypercholesterolemia and combined
hyperlipidemia. Am J Clin Nutr. 1995;61:141–148.
19. Jones PJ, Main BF, Frolich JJ. Response of cholesterol synthesis to cholesterol feeding in men with different apo E phenotypes. Metab Clin Exp. 1993;42:1065–1071.
20.
Mata P, Ordovas JM, Lopez-Miranda J, Lichtenstein AH,
Clevidence B, Judd JT, Scheafer EJ. ApoA-IV phenotype affects
diet-induced plasma LDL cholesterol lowering.
Arterioscler Thromb. 1994;14:884–891.
21.
McCombs RJ, Marcadis DE, Ellis J, Weinberg RB.
Attenuated hypercholesterolemic response to a
high-cholesterol diet in subjects heterozygous for the
apolipoprotein A-IV-2 allele. N Engl J Med. 1994;331:706–710.
22. Eusufzai S, Ngai CI, Holleran SF, Ginsberg HN. Effects of apolipoprotein B signal peptide polymorphism on the lipid response to reduction of dietary saturated fat. Circulation. 1996;94(suppl):I-97.
23. Connor WE, Lin DS. The intestinal absorption of dietary cholesterol by hypercholesterolemic (Type II) and normocholesterolemic humans. J Clin Invest. 1974;53:1062–1070.
24.
Miettinen TA, Kesaniemi YA. Cholesterol
absorption: regulation of cholesterol synthesis and
elimination and within-population variations of serum
cholesterol levels. Am J Clin Nutr. 1989;49:629–635.
25. Nestel PJ, Poyser A. Changes in cholesterol synthesis and excretion when cholesterol intake is increased. Metabolism. 1976;25:1591–1599.[Medline] [Order article via Infotrieve]
26.
Ginsberg H, Le NA, Mays C, Gibson J, Brown WV.
Lipoprotein metabolism in nonresponders to dietary
cholesterol.
Arteriosclerosis. 1981;1:463–470.
27.
Daumerie CM, Woollett LA, Dietschy JM. Fatty acids
regulate hepatic low density lipoprotein receptor activity through
redistribution of intracellular pools. Proc Natl Acad Sci
U. S. A.. 1992;89:10797–10801.
28. Woollett LA, Spady DK, Dietschy JM. Regulatory effects of the saturated fatty acids 6:0 through 18:0 on hepatic low density lipoprotein receptor activity in the hamster. J Clin Invest. 1992;89:1133–1141.
29.
Sorci-Thomas M, Wilson MD, Johnson FL, Williams DL,
Rudel LL. Studies on the expression of genes encoding apolipoproteins
B100 and B48 and the low density lipoprotein receptor in nonhuman
primates. Comparison of dietary fat and cholesterol.
J Biol Chem. 1989;264:9039–9045.
30. West DB, Goudey-Lefevre J, York B, Truett GE. Dietary obesity linked to genetic loci on Chromosomes 9 and 15 in a polygenic mouse model. J Clin Invest. 1994;94:1410–1416.
31. West DB, Waguespack J, York B, Goudey-Lefevre J, Price RA. Genetics of dietary obesity in AKR/JxSWR/J mice: segregation of the trait and identification of a linked locus on Chromosome 4. Mamm. Genome. 1994;5:546–552.[Medline] [Order article via Infotrieve]
32. Bouchard C, Tremblay A, Despres JP, Nadeau A, Lupien PJ, Theriault G, Dussault J, Moorjani S, Pineault S, Fournier G. The response to long-term overfeeding in identical twins. N England J Med. 1990;322:1477–1482.[Abstract]
33. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J, Weissenbach J. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 1996;380:152–154.[Medline] [Order article via Infotrieve]
34. Dietrich WF, Miller J, Steen R, Merchant MA, Damron-Boles D, Husain Z, Dredge R, Daly MJ, Ingalls KA, O'Connor TJ, Evans CA, DeAngelis MM, Levinson DM, Kruglyak L, Goodman N, Copeland NG, Jenkins NA, Hawkins TL, Stein L, Page DC, Lander ES. A comprehensive genetic map of the mouse genome. Nature. 1996;380:149–157.[Medline] [Order article via Infotrieve]
35. Jacob HJ, Brown DM, Bunker RK, Daly MJ, Dzau VJ, Goodman A, Koike G, Kren V, Kurtz T, Lernmark A, Levan G, Mao Y, Petterson A, Pravenec M, Simon JS, Szpirer C, Szpirer J, Trolliet MR, Winer ES, Lander ES. A genetic linkage map of the laboratory rat, Rattus norvegicus. Nature Genet. 1995;9:63–69.
36. Pravenec M, Gaugier D, Schott J-J, Buard J, Kren V, Bila V, Szpirer C, Szpirer J, Wang J-M, Huang H, St Lezin E, Spence MA, Flodman P, Printz M, Lathrop GM, Vergnaud G, Kurtz TW. A genetic linkage map of the rat derived from recombinant inbred strains. Mamm. Genome. 1996;7:117–127.[Medline] [Order article via Infotrieve]
37.
Lander ES, Schork NS. Genetic dissection of complex
factors. Science. 1994;265:2037–2048.
38.
Paterson AH. Molecular dissection of quantitative
traits: progress and prospects. Genome Res. 1995;5:321–333.
39. Human Genome Data Base (GDB). Johns Hopkins University, Baltimore, Maryland. Wide World Web (URL: http://gdbwww.gdb.org/gdb5.6/browser/docs/topq.html). 1997.
40. Mouse Genome Database (MGD). Mouse Genome Infromatics Project, The Jackson Laboratory, Bar Harbor, Maine. World Wide Web. (URL: http://www.informatics.jax.org/). 1997.
41.
Jaenisch R. Transgenic animals. Science. 1988;240:1468–1474.
42.
Capecchi MR. Altering, the genome by homologous
recombination. Science. 1989;244:1288–1292.
43. Wakefield MJ, Graves JAM. Comparative maps of vertebrates. Mamm Genome. 1996;7:715–716.[Medline] [Order article via Infotrieve]
44. Shih DM, Welch C, Lusis AJ. New insights into atherosclerosis from studies with mouse models. Molec Med Today. 1995;1:364–372.
45. Breslow JL. Mouse models of atherosclerosis. Science. 1996;272:685–688.[Abstract]
46. Lusis AJ. The mouse model for atherosclerosis. Trends Cardiovasc Med. 1993;3:135–143.
47. Kirk EA, Moe GL, Caldwell MT, Lernmark JA, Wilson DL, LeBoeuf RC. Hyper- and hypo-responsiveness to dietary fat and cholesterol among inbred mice: searching for level and variability genes. J Lipid Res. 1995;36:1522–1532.[Abstract]
48.
Paigen B. Genetics of responsiveness to high-fat and
high-cholesterol diets in the mouse. Am J Clin
Nutr. 1995;62:458S–462S.
49.
Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D.
Atherosclerosis susceptibility differences among
progenitors of recombinant inbred strains of mice.
Arterioscler. 1990;10:316–323.
50. Schemmel R, Mickelson O, Gill JL. Dietary obesity in rats: body weight and body fat accretion in seven strains of rats. J Nutr. 1970;100:1041–1048.
51. National Center for Biotechnology Information and the Whitehead Institute for Biomedical Research/MIT Center for Genome Research Database. Cambridge, Massachusetts. World Wide Web (http://www-genome.wi.mit.edu). 1997;.
52. Jacob HJ, Lindpaintner K, Lincoln SE, Kusumi K, Bunker RK, Mao Y-P, Ganten D, Dzau VJ, Lander ES. Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat. Cell. 1991;67:213–224.[Medline] [Order article via Infotrieve]
53. Pravenec M, Gauguier D, Schott J-J, Buard J, Kren V, Bila V, Szpirer C, Szpirer J, Wang J-M, Huang H, St Lezin E, Spence MA, Flodman P, Printz M, Lathrop GM, Vergnaud G, Kurtz TW. Mapping of quantitative trait loci for blood pressure and cardiac mass in the rat by genome scanning of recombinant inbred strains. J Clin Invest. 1995;96:1973–1978.
54. Bottger A, van Lith HA, Kren V, Krenova D, Bila V, Vorlicek J, Zidek V, Musilova A, Zdobinska M, Wang J-M, van Zutphen BFM, Kurtz TW, Pravenec M. Quantitative trait loci influencing cholesterol and phospholipid phenotypes map to chromosomes that contain genes regulating blood pressure in the spontaneously hypertensive rat. J Clin Invest. 1996;98:856–862.[Medline] [Order article via Infotrieve]
55. Warden CH, Fisler JS, Pace MJ, Svenson KL, Lusis AJ. Coincidence of genetic loci for plasma cholesterol levels and obesity in a multifactorial mouse model. J Clin Invest. 1993;92:773–779.
56. Purcell-Huyn DA, Weinreb A, Castellani LW, Mehrabian M, Doolittle MH, Lusis AJ. Genetic factors in lipoprotein metabolism: analysis of a genetic cross between inbred mouse strains NZB/BlNJ and SM/J using a complete linkage map approach. J Clin Invest. 1995;96:1845–1858.
57. Machleder D, Ivandic B, Welch C, Castellani L, Reue K, Lusis AJ. Complex genetic control of HDL levels in mice in response to an atherogenic diet: coordinate regulation of HDL levels and bile acid metabolism. J Clin Invest. 1997; in press.
58. Warden CH, Fisler JS, Shoemaker SM, Wen P-Z, Svenson KL, Pace MJ, Lusis AJ. Identification of four chromosomal loci determining obesity in a multifactorial mouse model. J Clin Invest. 1995;95:1545–1552.
59. Taylor BA, Phillips SJ. Detection of obesity QTLs on mouse Chromosomes 1 and 7 by selective DNA pooling. Genomics. 1996;34:389–398.[Medline] [Order article via Infotrieve]
60.
Khanuja D, Cheah Y-C, Hunt M, Nishina PM, Wang D Q-H,
Chen HW, Billheimer JT, Carey MC, Paigen B. Lith1, a major
gene affecting cholesterol gallstone formation among inbred
strains of mice. Proc Natl Acad Sci U. S. A.. 1995;92:7729–7733.
61.
Mehrabian M, Qiao J-H, Hyman R, Ruddle D, Laughton C,
Lusis AJ. Influence of the apo A-II gene locus on HDL levels and
fatty streak development in mice. Arterioscler Thromb. 1993;13:1–10.
62. Kren V, Pravenec M, Lu S, Krenova D, Wang J-M, Wang N, Merriouns T, Wong A, St Lezin E, Lau D, Szpirer C, Szpirer J, Kurtz TW. Genetic isolation of a region of Chromosome 8 that exerts major effects on blood pressure and cardiac mass in the spontaneously hypertensive rat. J Clin Invest. 1997;99:577–581.[Medline] [Order article via Infotrieve]
63.
Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC,
Shelanski S, Breslow J, Tall AR. Reduced high density lipoprotein
cholesterol in human cholesteryl ester transfer protein
transgenic mice. J Biol Chem. 1991;266:10796–10801.
64.
Jiang XC, Masucci-Magoulas L, Mar J, Lin M, Walsh A,
Breslow J, Tall A. Down-regulation of mRNA for the low density
lipoprotein receptor in transgenic mice containing the gene for human
cholesteryl ester transfer protein. J Biol Chem. 1993;268:27406–27412.
65.
Homanics GE, de Silva HV, Osada J, Zhang H, Wong H,
Borensztajn J, Maeda N. Mild dyslipidemia in mice following
targeted inactivation of the hepatic lipase gene. J Biol
Chem. 1995;270:2974–2980.
66. Jiang XC, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow J, Tall AR. Increased pre-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgress. J Clin Invest. 1996;98:2373–2380.[Medline] [Order article via Infotrieve]
67. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins University, Baltimore, MD. MIM Number. 210250: April 1997. World Wide Web (URL: http://www3.ncbi.nlm.nih.gov/omim/).
68. Harwood HJ, Chandler CE, Pellarin LD, Bangerter FW, Wilkins RW, Long CA, Cosgrove PG, Malinow MR, Marzetta CA, Pettini JL, Savoy YE, Mayne JT. Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin beta-tigogenin cellobioside (CP-88818; tiqueside). J Lipid Res. 1993;34:377–395.[Abstract]
69. McCarthy PA, DeNinno MP, Morehouse LA, Chandler CE, Bangerter FW, Wilson TC, Urban FJ, Walinsky SW, Cosgrove PG, Duplantier K, Etienne JB, Fowler MA, Lambert JF, O'Donnell JP, Pezzullo SL, Watson HA, Wilkins RW, Zaccaro LM, Zawistoski MP. 11-Ketotigogenin cellobioside (pamaqueside): a potent cholesterol absorption inhibitor in the hamster. J Med Chem. 1996;39:1935–1937.[Medline] [Order article via Infotrieve]
70.
Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S,
Schambelan M, Pitas RE, McGuire J, Herz J, Farese R Jr. Disruption of
the acyl-CoA:cholesterol acyltransferase gene in mice:
evidence suggesting multiple cholesterol esterification
enzymes in mammals. Proc Natl Acad Sci U. S. A.. 1996;93:14041–14046.
71. Yang H, Bard M, Bruner DA, Gleeson A, Deckelbaum RJ, Aljinovic G, Pohl TM, Rothstein R, Sturley SL. Sterol esterification in yeast: a two-gene process. Science. 1996;272:1353–1356.[Abstract]
72. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS. SREBP-1, a basic helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell. 1993;75:187–197.[Medline] [Order article via Infotrieve]
73.
Hua X, Yokoyama C, Wu J, Briggs MR, Brown MS, Goldstein
JL. SREBP-2, a second helix-loop-helix-leucine zipper protein that
stimulates transcription by binding to a sterol regulatory element.
Proc Natl Acad Sci U. S. A.. 1993;90:11603–11607.
74.
Tontonoz P, Kim JB, Graves RA, Spiegelman BM. ADD1: a
novel helix-loop-helix transcription factor associated with adipocyte
determination and differentiation. Mol Cell Biol. 1993;13:4753–4759.
75.
Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf
DJ. An oxysterol signaling pathway mediated by the nuclear receptor
LXR
. Nature. 1996;383:728–731.[Medline]
[Order article via Infotrieve]
76. Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nature Genet. 1997;15:269–272.[Medline] [Order article via Infotrieve]
77.
Masucci-Magoulas L, Goldberg IJ, Bisgaier CL,
Serajuddin H, Francone OL, Breslow JL, Tall AR. A mouse model of with
features of Familial Combined Hyperlipidemia.
Science. 1996;275:391–394.
This article has been cited by other articles:
 |
|
 |
|
  B. Smolkova, M. Dusinska, K. Raslova, M. Barancokova, A. Kazimirova, A. Horska, V. Spustova, and A. Collins Folate levels determine effect of antioxidant supplementation on micronuclei in subjects with cardiovascular risk Mutagenesis, November 1, 2004; 19(6): 469 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Lottenberg, V. S. Nunes, E. R. Nakandakare, M. Neves, M. Bernik, L. Lagrost, J. E. dos Santos, and E. Quintao The Human Cholesteryl Ester Transfer Protein I405V Polymorphism Is Associated with Plasma Cholesterol Concentration and Its Reduction by Dietary Phytosterol Esters J. Nutr., June 1, 2003; 133(6): 1800 - 1805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Kammerer, D. L. Rainwater, L. A. Cox, J. L. Schneider, M. C. Mahaney, J. Rogers, and J. L. VandeBerg Locus Controlling LDL Cholesterol Response to Dietary Cholesterol Is on Baboon Homologue of Human Chromosome 6 Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1720 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Corella, M. Guillen, C. Saiz, O. Portoles, A. Sabater, J. Folch, and J. M. Ordovas Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus J. Lipid Res., March 1, 2002; 43(3): 416 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Berglund The APOE gene and diets--food (and drink) for thought Am. J. Clinical Nutrition, April 1, 2001; 73(4): 669 - 670. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Denke, B. Adams-Huet, and A. T. Nguyen Individual Cholesterol Variation in Response to a Margarine- or Butter-Based Diet: A Study in Families JAMA, December 6, 2000; 284(21): 2740 - 2747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Goldberg, M. J. Busby-Whitehead, L. I. Katzel, R. M. Krauss, M. Lumpkin, and J. M. Hagberg Cardiovascular Fitness, Body Composition, and Lipoprotein Lipid Metabolism in Older Men J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2000; 55(6): 342M - 349. [Abstract] [Full Text]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||